Surgery and Radiosurgery for Acromegaly: A Review of Indications, Operative Techniques, Outcomes, and Complications

International Journal of Endocrinology - Tập 2012 - Trang 1-7 - 2012
Yvette Marquez1, Alexander Tuchman1, Gabriel Zada1
1Department of Neurosurgery, Keck School of Medicine, USC Medical Center, University of Southern California, 1200 North State Street, Suite 3300, Los Angeles, CA 90033, USA

Tóm tắt

Among multimodality treatments for acromegaly, the goals of surgical intervention are to balance maximal tumor resection while preserving normal pituitary function and maintaining patient safety. The resection of growth hormone-(GH-) secreting pituitary adenomas in the hands of experienced surgeons results in hormonal remission in 50–70% of patients. Acromegalic patients often have medical comorbidities and anatomical variations complicating anesthesia and surgical management. Despite these challenges, complications such as CSF leak or new hypopituitarism following surgery remain uncommon. Over the past decade, endoscopic approaches to pituitary tumors have improved visualization and facilitated identification of additional tumor using angled telescopes. Patients with persistent acromegaly following surgery require continued medical and/or radiation-based interventions. The adjunctive use of stereotactic radiosurgery offers hormonal remission in 40–50% of patients. In this article, the current preoperative evaluation, indications for surgery, surgical approaches, role of radiosurgery, complications, and remission criteria following operative resection of GH adenomas are reviewed.

Từ khóa


Tài liệu tham khảo

2003, Journal of Neurosurgery, 98, 719, 10.3171/jns.2003.98.4.0719

2008, Reviews in Endocrine and Metabolic Disorders, 9, 13, 10.1007/s11154-007-9060-2

10.1007/s11102-006-0409-4

10.1210/jc.2007-1191

10.1530/EJE-08-0267

10.1007/s11102-010-0273-0

1999, Annales de Medecine Interne, 150, 195

10.1210/er.2002-0022

10.1007/s11154-007-9064-y

10.1172/JCI39375

10.1530/EJE-08-0843

10.1210/jc.2009-2670

10.1530/eje.0.1500763

10.3171/2010.8.FOCUS10156

2000, Hormone Research, 53, 71, 10.1159/000023538

2003, Journal of Neurosurgery, 98, 350, 10.3171/jns.2003.98.2.0350

10.3171/2010.8.JNS10520

10.3171/2010.7.FOCUS10155

10.1007/s11102-008-0120-8

1999, British Medical Journal, 319, 588, 10.1136/bmj.319.7210.588

10.1097/00006123-199702000-00001

10.1210/jc.2011-0554

10.3171/2009.7.JNS09438

10.1016/0140-6736(90)91812-O

1998, Journal of Neurosurgery, 89, 353, 10.3171/jns.1998.89.3.0353

10.1227/01.neu.0000333297.41813.3d

10.1007/s11102-007-0078-y

10.3171/2010.7.FOCUS10124

10.1210/jc.86.9.4072

10.1210/jc.2008-0135

10.1530/EJE-07-0189

10.1002/cncr.22128

10.1111/j.1365-2265.2006.02513.x

10.1210/jc.2005-0311

10.3171/jns.2005.102.s_supplement.0119

2003, Neurosurgical Focus, 14, 1

10.1159/000048393

2001, European Journal of Endocrinology, 145, 717, 10.1530/eje.0.1450717

10.1016/0360-3016(95)00071-6

1951, Acta Chirurgica Scandinavica, 102, 316

10.3340/jkns.2009.45.3.157

2009, Canadian Journal of Neurological Sciences, 36, 468, 10.1017/S0317167100007800

10.1111/j.1365-2265.2006.02513.x

2007, Endocrine Practice, 13, 726, 10.4158/EP.13.7.726

10.1016/S1042-3680(02)00031-1

10.3171/jns.2007.106.5.833

10.1186/1756-9966-28-36

10.3171/2010.7.FOCUS10159

1999, Neurosurgery Clinics of North America, 10, 327, 10.1016/S1042-3680(18)30198-0

10.3171/2010.7.FOCUS10170

10.3171/2010.5.JNS091635

10.1210/jc.85.3.1287

10.1210/jc.2005-0331

10.1016/j.ijrobp.2007.08.018

10.1227/01.NEU.0000223512.09115.3E